TriSalus Life Sciences, Inc.
TLSIHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeTriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and. Valued at $221.1M, TLSI is a micro-cap name in its sector. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
Market Cap
$221.1M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-14.36
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.25
ROE
—
ROA
-36.8%
Cash
$46.3M
Total Debt
$34.4M
Free CF
-$10.9M
52W Change
-29.9%
Annual Financials
Cash vs Debt
Where TLSI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TLSI finished 17.91% below its 150-day moving average ($4.30) and 21.56% below its 200-day moving average ($4.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLSI overbought or oversold?
At the October 20, 2026 close, TLSI's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $46.3M in cash and $34.4M in debt, TLSI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$10.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $12.4M (2022) to $45.2M (2025), reflecting a 264% increase over the period.
The relatively low beta of 0.47 suggests TLSI is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence TriSalus Life Sciences, Inc.'s trajectory.